ACS Medicinal Chemistry Letters
Letter
(5) Han, K.-C.; Yeon Kim, S.; Gyeong Yang, E. Recent advances in
designing substrate-competitive protein kinase Inhibitors. Curr. Pharm.
Des. 2012, 18, 2875−2882.
(6) Pinna, L. A.; Ruzzene, M. How do protein kinases recognize their
substrates? Biochim. Biophys. Acta, Mol. Cell Res. 1996, 1314, 191−225.
(7) Obata, T.; Yaffe, M. B.; Leparc, G. G.; Piro, E. T.; Maegawa, H.;
Kashiwagi, A.; Kikkawa, R.; Cantley, L. C. Peptide and protein library
screening defines optimal substrate motifs for AKT/PKB. J. Biol. Chem.
2000, 275, 36108−36115.
(8) Luo, Y.; Smith, R. A.; Guan, R.; Liu, X.; Klinghofer, V.; Shen, J.;
Hutchins, C.; Richardson, P.; Holzman, T.; Rosenberg, S. H.; Giranda,
V. L. Pseudosubstrate peptides inhibit Akt and induce cell growth
inhibition. Biochemistry 2004, 43, 1254−1263.
(9) Litman, P.; Ohne, O.; Ben-Yaakov, S.; Shemesh-Darvish, L.;
Yechezkel, T.; Salitra, Y.; Rubnov, S.; Cohen, I.; Senderowitz, H.;
Kidron, D.; Livnah, O.; Levitzki, A.; Livnah, N. A novel substrate
mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth
in mice by blocking the PKB pathway. Biochemistry 2007, 46, 4716−
4724.
(22) Huang, X.; Begley, M.; Morgenstern, K. A.; Gu, Y.; Rose, P.;
Zhao, H.; Zhu, X. Crystal structure of an inactive Akt2 kinase domain.
Structure 2003, 11, 21−30.
(23) Ikediobi, O. N.; Davies, H.; Bignell, G.; Edkins, S.; Stevens, C.;
O’Meara, S.; Santarius, T.; Avis, T.; Barthorpe, S.; Brackenbury, L.;
Buck, G.; Butler, A.; Clements, J.; Cole, J.; Dicks, E.; Forbes, S.; Gray,
K.; Halliday, K.; Harrison, R.; Hills, K.; Hinton, J.; Hunter, C.;
Jenkinson, A.; Jones, D.; Kosmidou, V.; Lugg, R.; Menzies, A.;
Mironenko, T.; Parker, A.; Perry, J.; Raine, K.; Richardson, D.;
Shepherd, R.; Small, A.; Smith, R.; Solomon, H.; Stephens, P.; Teague,
J.; Tofts, C.; Varian, J.; Webb, T.; West, S.; Widaa, S.; Yates, A.;
Reinhold, W.; Weinstein, J. N.; Stratton, M. R.; Futreal, P. A.;
Wooster, R. Mutation analysis of 24 known cancer genes in the NCI-
60 cell line set. Mol. Cancer Ther. 2006, 5, 2606−2612.
(24) Qing-Bai, S.; Chandarlapaty, S.; Qing, Y.; Lobo, J.; Haskell, K.
M.; Leander, K. R.; DeFeo-Jones, D.; Huber, H. E.; Rosen, N. Breast
tumor cells with PI3K mutation or HER2 amplification are selectively
addicted to Akt signaling. PLoS One 2008, 3, 1−10.
(25) Kayser-Bricker, K. J.; Glenn, M. P.; Lee, S. H.; Sebti, S. M.;
Cheng, J. Q.; Hamilton, A. D. Non-peptidic substrate-mimetic
inhibitors of Akt as potential anti-cancer agents. Bioorg. Med. Chem.
2009, 17, 1764−1771.
(26) Pearce, L. R.; Komander, D.; Alessi, D. R. The nuts and bolts of
AGC protein kinases. Nat. Rev. Mol. Cell. Biol. 2010, 11, 9−22.
(10) Parang, K.; Cole, P. A. Designing bisubstrate analog inhibitors
for protein kinases. Pharmacol. Ther. 2002, 93, 145−157.
(11) Lavogina, D.; Enkvist, E.; Uri, A. Bisubstrate inhibitors of
protein kinases: from principle to practical applications. ChemMed-
Chem 2010, 5, 23−34.
(12) Johnson, D. S.; Weerapana, E.; Cravatt, B. F. Strategies for
discovering and derisking covalent, irreversible enzyme inhibitors.
Future Med. Chem. 2010, 2, 949−964.
(13) Barf, T.; Kaptein, A. Irreversible protein kinase inhibitors:
balancing the benefits and risks. J. Med. Chem. 2012, 55, 6243−6262.
(14) Yang, J.; Cron, P.; Good, V. M.; Thompson, V.; Hemmings, B.
A.; Barford, D. Crystal structure of an activated Akt/protein kinase B
ternary complex with GSK3-peptide and AMP-PNP. Nat. Struct. Mol.
Biol. 2002, 9, 940−944.
(15) Korwar, S.; Nguyen, T.; Ellis, K. C. Preparation and evaluation
of deconstruction analogues of 7-deoxykalafungin as AKT kinase
inhibitors. Bioorg. Med. Chem. Lett. 2014, 24, 271−274.
(16) Toral-Barza, L.; Zhang, W.-G.; Huang, X.; McDonald, L. A.;
Salaski, E. J.; Barbieri, L. R.; Ding, W.-D.; Krishnamurthy, G.; Hu, Y.
B.; Lucas, J.; Bernan, V. S.; Cai, P.; Levin, J. I.; Mansour, T. S.;
Gibbons, J. J.; Abraham, R. T.; Yu, K. Discovery of lactoquinomycin
and related pyranonaphthoquinones as potent and allosteric inhibitors
of AKT/PKB: mechanistic involvement of AKT catalytic activation
loop cysteines. Mol. Cancer Ther. 2007, 6, 3028−3038.
(17) Salaski, E. J.; Krishnamurthy, G.; Ding, W.-D.; Yu, K.; Insaf, S.
S.; Eid, C.; Shim, J.; Levin, J. I.; Tabei, K.; Toral-Barza, L.; Zhang, W.-
G.; McDonald, L. A.; Honores, E.; Hanna, C.; Yamashita, A.; Johnson,
B.; Li, Z.; Laakso, L.; Powell, D.; Mansour, T. S. Pyranonaph-
thoquinone lactones: a new class of AKT selective kinase inhibitors
alkylate a regulatory loop cysteine. J. Med. Chem. 2009, 52, 2181−
2184.
(18) Shearn, C. T.; Fritz, K. S.; Reigan, P.; Petersen, D. R.
Modification of Akt2 by 4-hydroxynonenal inhibits insulin-dependent
Akt signaling in HepG2 cells. Biochemistry 2011, 50, 3984−3996.
(19) Yellaturu, C. R.; Bhanoori, M.; Neeli, I.; Rao, G. N. N-
Ethylmaleimide inhibits platelet-derived growth factor BB-stimulated
Akt phosphorylation via activation of protein phosphatase 2A. J. Biol.
Chem. 2002, 277, 40148−40155.
(20) Rhodes, N.; Heerding, D. A.; Duckett, D. R.; Eberwein, D. J.;
Knick, V. B.; Lansing, T. J.; McConnell, R. T.; Gilmer, T. M.; Zhang,
S.-Y.; Robell, K.; Kahana, J. A.; Geske, R. S.; Kleymenova, E. V.;
Choudhry, A. E.; Lai, Z.; Leber, J. D.; Minthorn, E. A.; Strum, S. L.;
Wood, E. R.; Huang, P. S.; Copeland, R. A.; Kumar, R. Character-
ization of an Akt kinase inhibitor with potent pharmacodynamic and
antitumor activity. Cancer Res. 2008, 68, 2366−2374.
(21) Lindsley, C. W. The Akt/PKB family of protein kinases: a
review of small molecule inhibitors and progress towards target
validation: a 2009 update. Curr. Top. Med. Chem. 2010, 10, 458−477.
467
dx.doi.org/10.1021/ml500088x | ACS Med. Chem. Lett. 2014, 5, 462−467